What is the DeLLphi-306 Clinical Trial?

At your first visit(s), you will:

• Meet the clinical trial doctor and team at the location of the trial. This may be different from where you have received treatment in the past.
• Review and sign an informed consent to join the DeLLphi-306 clinical trial.
• Complete a general health assessment, including a physical exam, medical history, blood tests, and imaging.
• Have your tumor sampled.*

Approximately 400 participants will be randomly assigned to receive either tarlatamab (investigational drug) or placebo.

The tarlatamab group will:

• Receive tarlatamab by infusion (in a vein) once a week for the first 3 weeks and then once every 2 weeks afterwards in a 28-day cycle.
• Attend clinical trial appointments and check-ups to record your progress.

The placebo group will:

• Receive a placebo by infusion (in a vein) once a week for the first 3 weeks and then once every 2 weeks afterwards in a 28-day cycle.
• Attend clinical trial appointments and check-ups to record your progress.

You will continue to receive treatment in this clinical trial based on the results of your bloodwork and imaging. Your participation in this clinical trial may end if:

1. Your cancer gets worse.
2. You experience serious side-effects from treatment.
3. You decide to stop the trial at any time.

The clinical trial team will schedule a follow-up visit with you approximately 6 weeks after your last trial treatment.

The clinical trial team may follow-up with you by phone or ask you to visit the clinic approximately once every 3 months.